Worksport Ltd
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Audited Consolidated Financial Statements
1. Description of Business and Significant Accounting Policies
The Company’s corporate history and business overview are described in detail in our most recent registration statement on Form S-3, filed with the SEC on January 20, 2026, which is incorporated herein by reference. For a description of material developments the Company has undertaken since that time, see Corporate History of Part I Item 1, Business of this Report.
**Basis of presentation –**The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).
**Consolidation **– The Company’s consolidated financial statements consolidate the accounts of the Company. All intercompany transactions, balances and unrealized gains or losses from intercompany transactions have been eliminated upon consolidation.
Foreign currency translation and presentation – The consolidated financial statements are presented in USD. The functional currency of the Company and all its subsidiaries is USD. Transactions denominated in foreign currencies are initially recorded in the functional currency using exchange rates in effect at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency using exchange rates in effect at the dates of the transactions. All exchange gains and losses are included in the statement of operations and comprehensive loss.
Use of estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates and assumptions.
**Revenue recognition –**In accordance with ASC 606 , sales are recognized when (1) products are shipped, with no right of return except for defective products, and the title and risk of loss has passed to customers; and (2) when they are delivered based on the terms of the sale, and there is an identifiable contract with a customer with defined performance obligations, the transaction price is determinable, and the entity has fulfilled its performance obligation. Revenue related to shipping and handling costs billed to customers is included cost of sales and presented net of related shipping and handling costs.
**Cost of sales –**Includes costs of products sold, which include but are not limited to purchased product, raw material, direct labor, shipping and handling costs, depreciation and amortization, indirect costs and overhead charges.
Research and development – Research and development costs are expensed as incurred and include consulting and material costs.
Advertising costs – The Company expenses advertising costs as incurred and includes expenses in sales and marketing.
Share-based payments - The Company offers a share option plan for its directors, officers, employees, and consultants. ASC 718 prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values at the time of grant. Compensation expense is included in general and administrative expenses. Compensation expense is recognized over the estimated period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company elected to account for forfeitures when the forfeiture of the underlying awards occur.
Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of the performance commitment date or performance completion date.
**Income taxes -**Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes.
Tax positions initially need to be recognized in the financial statements when it is more likely than not the positions will be sustained upon examination by the tax authorities.
The Company recognizes interest accrued related to unrecognized tax benefits in interest expenses and penalties in operating expenses.
The Company treats tax on the Global Intangible Low-Tax Income (“GILTI”) as a current period cost included in tax expense in the year incurred. The Company does not measure the impact of GILTI in the determination of deferred taxes.
Cash and cash equivalents - All highly liquid investments with an original maturity of three months or less are considered cash equivalents. Cash and cash equivalents in financial institutions may exceed insured limits at various times during the year and subject the Company to concentrations of credit risk. There isno restricted cash at December 31, 2025 or 2024.
1. Description of Business and Significant Accounting Policies(continued)
**Accounts receivable, net **– Accounts receivable primarily consists of amounts that are due and payable from distributors, wholesalers, and private label partners. Receivables are stated at net realizable value, which approximates fair value. Receivables are reduced by an allowance for credit losses for amounts that may be uncollectible in the future. The allowance is determined by considering factors such as historical experience, credit quality, age of the accounts receivable, economic conditions and reasonable forecasted financial information that may affect a customer’s ability to pay. The allowance for credit losses at December 31, 2025 and 2024 was $15,000.
**Inventories -**Inventories are stated at the lower of cost or net realizable value. The cost of inventory is measured on a weighted average cost method. Cost includes purchase price of materials, freight, and related costs required to bring the goods to Company warehouses. Inventories are reviewed to determine if quantities are in excess of forecasted usage or if they become obsolete.
**Property and equipment, net –**Property and equipment are measured at cost. Maintenance and repair costs are charged to expense when incurred. Depreciation is recognized on a straight-line method based on the following estimated useful lives:
| Furniture and equipment | 5 years |
|---|---|
| Automobile | 5 years |
| Computers | 3 years |
| Leasehold improvements | 15 years or lease term, if shorter |
| Manufacturing equipment | 5-15 years |
| Building | 15 years |
Right-of-use assets - The Company recognizes leases in accordance with ASC 842, which requires lessees to recognize operating leases on the balance sheet as right-of-use assets and lease liabilities based on the value of the discounted future lease payments.
Intangible assets – Patents and other intangibles are amortized using the straight-line method over their estimated useful lives. Intangible assets, such as trademarks with indefinite lives, are not amortized.
Valuation of long-lived assets – Intangible assets are evaluated for impairment at least annually or when events or circumstances arise that indicate the existence of impairment. The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. When indicators of impairment exist, the Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment, and actual results may differ from assumed and estimated amounts. During the years ended December 31, 2025 and 2024, the Company had no impairment losses related to intangible assets.
1. Description of Business and Significant Accounting Policies (continued)
**Product warranties -**The Company currently offers a three-year limited warranty against defective products out-of-the-box. Customers who are not satisfied with their purchase may attempt to have their purchases reimbursed outside of the warranty period.
**Financial instruments **- ASC 825, requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts receivable, and accounts payable and accrued liabilities, approximates their fair values because of the short-term maturities of these instruments. The carrying value of the loans payable approximate fair value as its interest rate fluctuates with market interest rates. We do not hold or issue financial instruments for trading purposes.
**Related party transactions **- All transactions with related parties are in the normal course of operations and are measured at the exchanged amount.
Reclassifications – Certain prior year amounts have been reclassified to conform to current year’s presentation. The Company reclassified professional fees of $3,136,869 and $3,030,931 for the fiscal years ended December 31, 2025 and 2024, respectively, which were classified from professional fees to general and administrative expense on the Consolidated Statements of Operations and Comprehensive Loss. This change improves the disclosure of costs as the company continues to increase its size and decrease its reliance on consulting arrangements with third parties to grow its operations.
Recent accounting pronouncements
Recent accounting pronouncements adopted
In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-09 “Income Taxes (Topics 740):Improvements to Income Tax Disclosures” to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for our annual periods beginning January 1, 2025, with early adoption permitted. We adopted this standard for the year ended December 31, 2025, and applied the amendments on a prospective basis. Refer to Note 8, Income Taxes. The adoption of this standard did not have a material effect on the financial statements and related disclosures.
In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280):Improvements to Reportable Segment Disclosures” which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. We adopted this standard for the year ended December 31, 2024, and applied the amendments retrospectively to all prior periods presented. Refer to Note 16, Segment Reporting. The adoption of this standard did not have a material effect on the financial statements and related disclosures.
Recent accounting pronouncements not yet adopted
In November 2024, the FASB issued ASU 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures” to enhance disclosure of specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06,Intangibles- Goodwill and Other- Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This ASU removes all references to prescriptive and sequential software development stages and will now require PBEs to start capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform the function intended. The ASU also specifies that the disclosures in Subtopic 360-10, Property, Plant, and Equipment- Overall are required for all capitalized internal-use software costs. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the disclosure requirements of this standard and the impact on its consolidated financial statements.
In December 2025, the FASB issued ASU 2025-11,Interim Reporting (Topic 270): Narrow-Scope Improvements. This ASU amends Topic 270, by improving the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional guidance on what disclosures should be provided in interim reporting periods. Additionally, the amendment requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the disclosure requirements of this standard and the impact on its consolidated financial statements.
The Company considers the applicability and impact of all ASUs. ASUs not listed were assessed and determined to be either not applicable or had or are expected to have an immaterial impact on the financial statements and related disclosures.
2. Going Concern
As of December 31, 2025, the Company had $5,945,894 in cash and cash equivalents. The Company also has availability on its revolving line of credit of $3,448,016. The Company has generated only limited revenues and has relied primarily upon capital generated from public and private offerings of its securities. Since the Company’s acquisition of Worksport in 2014, it has never generated a profit. As of December 31, 2025, the Company had an accumulated deficit of $83,873,790.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. During the year ended December 31, 2025, the Company had net losses of $19,352,297 (2024 - $16,163,789). As of December 31, 2025, the Company had working capital of $10,061,578 (2024 – $7,304,110) and had an accumulated deficit of $83,873,790 (2024 - $64,476,966). The Company has not generated profit from operations since inception and to date has relied on debt and equity financing for continued operations. The Company’s ability to continue as a going concern is dependent upon the ability to generate cash flows from operations and obtain equity and/or debt financing. The Company intends to continue funding operations through equity and debt financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements in the long term. There can be no assurance that the steps management is taking will be successful.
The Company has historically operated at a loss, although that may change as sales volumes increase and margins improve. As of December 31, 2025, the Company had cash and cash equivalents of $5,945,894 (2024 - $4,883,099). Despite the Company having completed its purchasing of large manufacturing machinery for phase one output levels, operational costs are expected to remain elevated and, thus, further decrease cash and cash equivalents. Concurrently, the Company intends to continue its ramp-up of manufacturing and increasing sales volumes in 2026, which should mitigate the effects of operational costs on cash and cash equivalents as it releases new product lines; this view is supported by the fact that the manufacturing facility of the Company was completed for initial production output in 2023 and quickly began improving output and sales during 2024 and 2025.
The Company has successfully raised cash, and it is positioned to do so again if deemed necessary or strategically advantageous. During the year ended December 31, 2021, the Company, through its Reg-A public offering, private placement offering, underwritten public offering, and exercises of warrants, raised an aggregate of approximately $32,500,000. On September 30, 2022, the Company filed a shelf registration statement on Form S-3, which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 13, 2022 (the “Shelf Registration Statement”), allowing the Company to issue up to $30,000,000 of common stock and prospectus supplement covering the offering, issuance and sale of up to $13,000,000 of common stock that may be issued and sold under an At The Market Offering Agreement dated September 30, 2022 (“ATM Agreement”), with H.C. Wainwright & Co., LLC, as the sales agent (“HCW”). Pursuant to the ATM Agreement, HCW is entitled to a commission equal to 3.0% of the gross sales price of the shares of common stock sold. Through December 31, 2025, the Company cumulatively sold and issued 872,027 shares of common stock in consideration for net proceeds of $6,751,381 under the ATM Agreement. This agreement was amended in November 2025.
On November 2, 2023, the Company consummated a registered direct offering pursuant to which the Company issued 192,500 shares of common stock and 157,500 pre-funded warrants to an institutional investor for a total net proceeds of $4,261,542. Concurrently with the registered direct offering, the Company issued the same institutional investor 700,000 warrants in a private sale. The warrants are exercisable for 700,000 shares of common stock for $13.40 per share six months after issuance and until five and a half (5.5) years from the issuance date, subject to beneficial ownership limitations as described in the warrants. The Company registered the 700,000 shares of common stock underlying the warrants on a Form S-1 (333-276241) which was declared effective by the SEC on December 29, 2023.
On March 20, 2024, the Company consummated a registered direct offering pursuant to which the Company issued 237,224 shares of common stock and 147,789 pre-funded warrants to the same institutional investor as in the Company’s registered direct offering on November 2, 2023, for a total net proceeds of $2,629,083. Concurrently with the registered direct offering, the Company issued the institutional investor 770,026 warrants in a private sale. The warrants are exercisable for 770,026 shares of common stock for $7.40 per share six months after issuance until five and a half years from the issuance date, subject to beneficial ownership limitations as described in the warrants. The Company registered the 770,026 shares of common stock underlying the warrants on a Form S-1 (333-278461) which was declared effective by the SEC on April 8, 2024.
On May 29, 2024, Worksport sent an inducement letter to a shareholder offering an option to exercise their warrants at a reduced exercise price of $5.198 per warrant. In turn for doing so, Worksport offered the shareholder new warrants to purchase up to 1,295,000 shares of common stock with an exercise price of $5.198. The warrants had a term of 5.5 years, with a 6-month required holding period prior to exercise.
On December 13, 2024, the Company filed a prospectus supplement to amend and supplement a prospectus supplement dated as of November 5, 2024, as well as the prospectus supplement dated as of October 13, 2022, and the prospectus dated as of October 13, 2022 to increase the maximum amount of shares that we are eligible to sell pursuant to the ATM Agreement under General Instruction I.B.6. to $4,962,092 of shares of our common stock not including whatever had been sold prior to this filing date.
On February 27, 2025, Worksport entered into a warrant inducement agreement with a shareholder to exercise 755,558 of 1,295,000 May 2024 Warrants at a price of $5.198 per share. The remaining unexercised 539,442 warrants are included in share subscription payable. In return, the Company issued 1,424,500 new 2025 Inducement Warrants. Each Inducement Warrant has an exercise price of $6.502, will become exercisable six months after issuance, and have a 5.5-year life. Worksport raised approximately $6,731,000 in gross proceeds before fees and expenses, with the funds earmarked for general corporate and working capital purposes.
On June 13, 2025, Worksport completed the initial closing of its Regulation A offering whereby up to 3,100,000 Units may be sold at an offering price of $3.25 per unit. Each Unit consists of one share of 8% Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”) and one warrant for the right to purchase one (1) share of common stock, $0.001 par value with an exercise price of $4.50 per share. The qualified Regulation A offering is expected to generate gross proceeds of $10,000,000. The Company completed the Regulation A offering in October 2025. The Company completed 32 tranches and received proceeds of $9,092,414 (net of issuance costs of $899,997).
On November 14, 2025, Worksport filed a registration statement containing two prospectuses: (1) a base prospectus, which covers the potential offering, issuance, and sale by the registrant of up to a maximum aggregate offering price of $30,000000 of the registrant’s common stock, preferred stock, debt securities, warrants and units, and (2) an “at the marketing offering” offering prospectus supplement, which covers issuance and sale by the Company of up to a maximum aggregate offering price of $4,000,000 of the Company’s common stock that may be issued and sold under that certain At the Market Offering agreement, dated September 22, 2022, as amended on November 14, 2025 between the Company and H.C. Wainwright & Co., LLC, as sales agent.
On December 11, 2025, the Company entered into a warrant inducement agreement (the “Inducement”) with the holder of existing warrants to purchase an aggregate of 2,194,526 shares at a reduced exercise price of $2.90. Pursuant to the Inducement, the exercising holder of the existing warrants received 3,840,421 inducement warrants and the Company received $6,364,000 from the exercise of the existing warrants. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental fair value of $4,485,000 is recorded as a non-cash deemed dividend. The proceeds of the warrant inducement and issuance of 916,000 shares of common stock are recorded as additional paid in capital. The obligation to issue the remaining 1,278,526 shares is recorded as a component of equity.
To date, the Company’s principal sources of liquidity consist of net proceeds from public and private securities offerings and cash exercises of outstanding warrants. Management is focused on transitioning towards revenue as its principal source of liquidity by growing existing product offerings as well as the Company’s customer base. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for planned operations or future business developments. Future business development and demands may lead to cash utilization at levels greater than recently experienced. The Company may need to raise additional capital in the future. However, the Company cannot provide assurances it will be able to raise additional capital on acceptable terms, or at all.
The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. Still, certain factors indicate the existence of a material uncertainty that cast substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. These adjustments could be material.
3. Inventories
Inventory consists of the following at December 31, 2025 and 2024:
| 2025 | 2024 | |
|---|---|---|
| Raw materials | $5,405,618 | $3,373,704 |
| Finished goods | 3,368,509 | 1,343,006 |
| Work in progress | 756,544 | 473,344 |
| Inventories, net | $9,530,671 | $5,190,054 |
4. Property and Equipment
Major classes of property and equipment at December 31, 2025 and 2024 are as follows:
| 2025 | 2024 | |
|---|---|---|
| Building | $6,079,410 | $6,079,410 |
| Manufacturing equipment | 6,519,571 | 5,830,999 |
| Land | 2,239,405 | 2,239,405 |
| Leasehold improvements | 489,722 | 862,504 |
| Product molds | 524,476 | 524,476 |
| Warehouse equipment | 503,297 | 512,700 |
| Electrical equipment | 183,977 | 185,261 |
| Automobile | 242,642 | 172,645 |
| Furniture | 149,883 | 154,065 |
| Computers | 101,058 | 114,786 |
| Property and equipment, at cost | 17,033,441 | 16,676,251 |
| Less accumulated depreciation | (4,344,953) | (3,032,025) |
| Property and equipment, net | $12,688,488 | $13,644,226 |
During the fiscal years ended December 31, 2025 and 2024, the Company recognized depreciation expense of $1,448,472 and $1,367,445, respectively.
During the fiscal year ended December 31, 2025, the Company recognized a non-cash loss on disposal of property and equipment of $296,726. The loss primarily relates to leasehold improvements whereby the underlying lease agreement was not renewed. This loss is included in the Consolidated Statement of Operations and Comprehensive Loss as a component of general and administrative expense.
5. Intangible Assets
Intangible assets consist primarily of costs incurred in establishing the Company’s intellectual property and other non-physical rights, including patents and patent applications (including related utility patents and design registrations), trademarks and trade names, copyrights, certain licenses and other contractual rights, and capitalized software and qualifying website and application development costs. The Company’s utility patents and design registrations were issued between 2014 and 2024. The patents and software are amortized on a straight-line basis over their useful life. The Company’s trademark, licenses, and other indefinite life intangible assets are reassessed every year for impairment. The Company determined that impairment is not necessary for the current year ended December 31, 2025. The components of intangible assets as of December 31, 2025 and 2024 are as follows:
| 2025 | 2024 | |
|---|---|---|
| Software | $1,150,000 | $1,150,000 |
| License | 218,329 | 103,329 |
| Patent | 62,706 | 62,706 |
| Trademark | 5,150 | 5,150 |
| Other | 243,769 | 29,451 |
| Intangible assets, gross carrying amount | 1,679,954 | 1,350,636 |
| Less accumulated amortization | (783,423) | (397,587) |
| Intangible assets, net | $896,531 | $953,049 |
Amortization expense for the fiscal years ended December 31, 2025 and 2024 was $385,836 and $385,840, respectively.
5. Intangible Assets (continued)
Estimated amortization of the patent and software over the next five years and beyond December 31, 2025 is as follows:
| 2026 | $386,000 |
| 2027 | $3,000 |
| 2028 | $3,000 |
| 2029 | $2,000 |
| 2030 | $2,000 |
| Thereafter | $33,000 |
6. Prepaid Expenses and Deposits
As of December 31, 2025 and 2024, prepaid expenses and deposits consists of the following:
| 2025 | 2024 | |
|---|---|---|
| Consulting, services and advertising | $222,922 | $35,740 |
| Insurance | 104,421 | 65,938 |
| Deposits | 203,518 | 90,514 |
| Prepaid expenses and deposits | $530,861 | $192,192 |
Deposits include prepayments for research and development services, manufacturing equipment and raw materials used in the production of finished goods.
7. Shareholders’ Equity (Deficit)
The Company is authorized to issue up to 55,000,000 shares of capital stock, par value $0.001 per share. Capital stock is divided into two classes designated as common stock and preferred stock.
Common stock– The Company is authorized to issue up to 45,000,000 shares of common stock.
*Preferred stock –*The Company is authorized to issue up to 10,000,000 shares of preferred stock. The Board of Directors may authorize, without further shareholder action, the issuance of preferred stock in one or more classes or series. Preferred stock ranks senior to common stock with respect to payment of dividends and the distribution of assets on liquidation. Each class or series of preferred stock, when issued, must include its designation and a description of certain rights, including voting privileges, dividend preferences, conversion features, restrictions and redemption rights.
| - | During 2019, the Company created and issued 100 shares of its Series A preferred stock. Series A preferred shareholders vote together as a single class and are entitled to 51% of the voting rights on all matters regardless of the number of Series A preferred shares outstanding. Series A preferred stock does not have conversion rights, is not entitled to receive dividends nor receive any liquidation preferences. |
| - | During 2020, the Company created the Series B preferred stock. Series B preferred shareholders have the right to vote for each share of common stock outstanding after the issuance date. Series B preferred stock does not have conversion rights, is not entitled to receive dividend preferences nor receive any liquidation preferences. As of December 31, 2025, the Company has not issued shares of Series B preferred stock. |
| - | During 2025, the Company created its Series C preferred stock for its Regulation A offering. Refer to Note 14, Warrants for a description of units available in the Regulation A offering. Series C preferred stock ranks senior to common stock and future classes or series of preferred stock as to dividend and liquidation rights. Series C preferred shareholders may convert holdings on a 1:1 basis to common stock at any time. Series C preferred shareholders are entitled to cumulative dividends at a rate of 8.00% of the $3.25 liquidation preference per share per year for a period of two (2) years from the date of issuance. As of December 31, 2025, the Company issued 3,074,586 shares of Series C preferred stock and converted 2,646,774 Series C preferred shares to common stock at the shareholder’s request. The Company recognized dividends paid and payable to Series C preferred shareholders as of December 31, 2025, of $17,192 and $27,335, respectively. |
During year ended December 31, 2025, the following transactions occurred:
During the year ended December 31, 2025, the Company sold 110,619 shares of common stock for total net proceeds of $504,372. The sale of shares was in connection with the Shelf Registration Statement and the ATM Agreement described in Note 2, Going Concern.
The Company recognized consulting expense of $13,000 and salary expense of $4,843 to share subscriptions payable from restricted shares and stock options to be issued. As of December 31, 2025, the $17,843 of the restricted shares have not been issued. The Company recognized consulting expense of $215,667 related to warrants issued pursuant to a service agreement.
During the year ended December 31, 2025, in connection with the inducement of 1,295,091 warrants at $5.198 per share, the Company sold 1,424,500 warrants exercisable at $6.502 per share. The Company received proceeds of $6,731,410 before deducting placement agent fees of $346,570 and other offering expenses payable by the Company upon the exercise of the May 2024 Existing Warrants. In addition, in connection with the inducement of 2,194,526 warrants at $2.90 per share, the Company sold 770,026 warrants exercisable at $7.40 per share and 1,424,500 warrants exercisable at $6.502 per share. The Company received proceeds of $6,364,125 before deducting placement aging fees of $328,206 and other offering expenses payable by the Company upon the exercise of February 2024 and February 2025 warrants, respectively.
During the year ended December 31, 2025, in connection with the Regulation A offering of up to 3,100,000 Units at an offering price of $3.25 per Unit, the Company issued 3,074,586 Units, received proceeds of $9,092,414 (net of issuance costs of $899,997).
During the year ended December 31, 2025, certain Series C preferred shareholders converted 2,646,774 shares into the Company’s common stock.
7. Shareholders’ Equity (Deficit)(continued)
During year ended December 31, 2024, the following transactions occurred:
During the year ended December 31, 2024, the Company sold 758,995 shares of common stock for a total net proceeds of $6,032,789. The sale of shares was in connection with the shelf registration statement on Form S-3 effective on October 13, 2022, allowing the Company to issue up to $30,000,000 of common stock and prospectus supplement covering the offering, issuance and sale of up to $13,000,000 of common stock that may be issued and sold under an At The Market Offering Agreement dated as of September 30, 2022.
The Company recognized consulting expense of $747,366 to share subscriptions payable from restricted shares and stock options to be issued. As of December 31, 2024, the restricted shares have not been issued. As of December 31, 2024, the Company issued 84,594 restricted shares with a value of $438,992.
During the year ended December 31, 2024, in connection with the sale of 237,224 shares of common stock, the Company also sold 147,789 pre-funded warrants and issued 770,026 warrants exercisable for a total of 770,026 shares of common stock for $0.001 and $7.40, respectively, per share. The Company received net proceeds of $1,093,492 associated with the sale of the pre-funded warrants. The pre-funded warrants are immediately exercisable until all the pre-funded warrants are exercised. During the period,147,790 warrants were exercised for 147,790 shares of common stock for $150. Refer to Note 14, Warrants.
During the year ended December 31, 2024, the Company closed a sale of 95,000 shares of common stock for proceeds of $380,000. In connection with the sale of common stock, the Company issued 190,000 warrants. Refer to Note 14, Warrants. As of December 31, 2024, the shares have not been issued.
8. Income Taxes
The Company adopted ASU 2023-09 on a prospective basis as of January 1, 2025, which resulted in additional income tax disclosures for the rate reconciliation and related to income taxes paid for 2025. Given that the Company elected to adopt ASU 2023-09 prospectively, the 2024 rate reconciliation is not disaggregated in accordance with 2023-09 and the income taxes paid is not presented by jurisdiction.
The following table summarizes disaggregated loss from continuing operations before income tax expense:
| Domestic · Foreign · Total | ||||
|---|---|---|---|---|
| Loss before income tax expense from continuing operations | ||||
| Federal | $(10,934,578) | $ | - | $(10,934,578) |
| State | (1,712,911) | - | (1,712,911) | |
| Foreign | - | (6,704,808) | (6,704,808) | |
| Total continuing operation | $(12,647,489) | $(6,704,808) | $(19,352,297) | |
Income tax expense (benefit) from continuing operations or the fiscal year ended December 31, 2025 consisted of the following:
| Current · Deferred · Total | ||||||
|---|---|---|---|---|---|---|
| Federal | $ | - | $(2,042,695) | $(2,042,695) | ||
| State | - | (516,688) | (516,688) | |||
| Foreign | - | (1,641,617) | (1,641,617) | |||
| $ | - | $(4,201,000) | $(4,201,000) | |||
| Valuation allowance | - | 4,201,000 | 4,201,000 | |||
| Income tax expense | $ | - | $ | - | $ | - |
The provision for income taxes for the fiscal year ended December 31, 2025 differed from the amount computed by applying the federal statutory income tax rate due to:
| Amount · Percent | |||
|---|---|---|---|
| U.S. Federal Statutory Income Tax and Rate | $(2,656,369) | (21.0)% | |
| State and Local Income Taxes, Net of Federal Income Tax Effect (1) | (364,757) | (0.5)% | |
| Foreign Tax Effects | (1,641,617) | (2.1)% | |
| Changes in Unrecognized Tax Benefits | |||
| Share compensation | 345,850 | 0.5% | |
| Other | 19,201 | 0.0% | |
| Tax Credits | |||
| Research and Development Tax Credit | (40,000) | (0.00)% | |
| Nontaxable and nondeductible items | |||
| Share Based Compensation | 131,152 | 0.2% | |
| Other | 5,539 | 0.0% | |
| Changes in Valuation Allowance | 4,201,000 | 22.9% | |
| Effective Tax Rate | $ | - | 0.0% |
| (1) | State taxes in Florida, New York, New Jersey and Massachusetts make up the majority (more than 50%) of the tax effect of this category. |
8. Income Taxes(continued)
A reconciliation of the statutory U.S. federal income tax rate to the effective tax rate for the period before the adoption of ASU 2023-09 was as follows:
| Federal statutory income tax rate | 21.0% | |
|---|---|---|
| State taxes, net of federal benefits | (0.7)% | |
| Share based compensation | 1.3% | |
| Other | 1.3% | |
| Effective income tax rate | 22.9% | |
| Income tax benefit | (3,383,000) | |
| Estimated research and development credit | (90,000) | |
| Increase in valuation allowance | 3,473,000 | |
| Provision for income taxes | $ | - |
Income taxes paid (net or refunds) consisted of the following:
| Federal · $ · - | |
|---|---|
| State | 2,420 |
| Foreign | - |
| Total income taxes paid | 2,420 |
Income taxes paid (net of refunds) was $62 for the year ended December 31, 2024.
Income taxes paid, net of refunds, exceeded five (5) percent of total income taxes paid (net of refunds) in the following jurisdictions:
| State | |
|---|---|
| New Jersey | $2,138 |
| New York | 150 |
| Massachusetts | 132 |
| State | 2,420 |
| Foreign | - |
| Total income taxes paid | 2,420 |
The tax effects of temporary differences that give rise to the deferred income tax assets at December 31, 2025 and 2024 are as follows:
| 2025 · 2024 | ||||
|---|---|---|---|---|
| Net operating loss carry forwards | $13,618,000 | $10,029,000 | ||
| Differences in basis of depreciation of property and equipment | 417,000 | 465,000 | ||
| Share based compensation | 2,012,000 | 1,352,000 | ||
| Research and development credit | 180,000 | 180,000 | ||
| Deferred tax asset, gross | 16,227,000 | 12,026,000 | ||
| Deferred tax assets not recognized | (16,227,000) | (12,026,000) | ||
| Net deferred tax asset | $ | - | $ | - |
Deferred income taxes within each jurisdiction on the balance sheets at December 31, 2025 and 2024 are as follows:
| 2025 · 2024 | ||||
|---|---|---|---|---|
| United States | $10,118,000 | $7,488,000 | ||
| Canada | 6,109,000 | 4,538,000 | ||
| Deferred income taxes | 16,227,000 | 12,026,000 | ||
| Valuation allowance | (16,227,000) | (12,026,000) | ||
| Net deferred tax asset | $ | - | $ | - |
The Company has non-capital losses carried forward of approximately $58,867,000 available to reduce future years’ taxable income. These losses will expire as follows:
| United States · Canada · Total | ||||
|---|---|---|---|---|
| 2034 | $53,000 | $183,000 | $236,000 | |
| 2035 | 161,000 | 368,000 | 529,000 | |
| 2036 | 868,000 | 262,000 | 1,130,000 | |
| 2037 | 1,472,000 | 59,000 | 1,531,000 | |
| 2038 | - | 520,000 | 520,000 | |
| 2039 | - | 193,000 | 193,000 | |
| 2040 | - | 718,000 | 718,000 | |
| 2041 | - | 2,854,000 | 2,854,000 | |
| 2042 | - | 3,771,000 | 3,771,000 | |
| 2043 | 2,686,000 | 2,686,000 | ||
| 2044 | - | 5,032,000 | 5,032,000 | |
| 2045 | - | 6,197,000 | 6,197,000 | |
| Non-capital losses carried forward Total | $2,554,000 | $22,843,000 | $25,397,000 | |
| Never expire | $33,470,000 | $ | - | $33,470,000 |
8. Income Taxes(continued)
Realization of deferred tax assets is dependent, in part, upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers projected future taxable income, tax planning strategies and carryback opportunities in making its assessment of the recoverability of tax assets. Net operating loss carryforwards of approximately $58,867,000 may be offset against future taxable income. No tax benefit from these losses have been reported in the December 31, 2025 consolidated financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.
Due to change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years.
The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740.
The Company does not expect the amount of unrecognized tax benefits to materially change within the next twelve months.
The Company is subject to income taxes in the U.S. and in various states and foreign jurisdictions. Tax regulations with each jurisdiction are subject to the interpretation of the related tax laws and regulations and require the application of significant judgment. The Company is no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for tax years ending before December 31, 2020 in the U.S. The Company is no longer subject to non-U.S. income tax examinations by tax authorities for tax years ending before December 31, 2014.
9. Financial Instruments and Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an ordinary transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate fair value. The definition of the fair value hierarchy is as follows:
Level 1 – Quoted prices in active markets for identical assets and liabilities.
Level 2 – Observable inputs other than quoted prices in active markets for similar assets and liabilities.
Level 3 – Inputs for which significant valuation assumptions are unobservable in a market and therefore value is based on the best available data, some of which is internally developed and considers risk premiums that a market participant would require.
The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, revolving line of credit, and long-term debt. The fair values of cash and cash equivalents, accounts receivable and accounts payable approximate their carrying value because of the short-term nature of these instruments. The Company’s revolving line of credit and long-term debt are based on a variable interest rate, and are reflected in the financial statements at carrying value which approximates fair value at December 31, 2025. The fair value of the revolving line of credit and long-term debt is classified as Level 2 within the fair value hierarchy.
The Company is exposed to market risks such as fluctuation in foreign currency exchange rates and interest rates. Derivative instruments may be used to offset some of the effects of these market risks on the expected future cash flows and on certain existing assets and liabilities. The Company may choose not to hedge certain exposures for a variety of reasons including, but not limited to, accounting considerations and the prohibitive economic cost of hedging particular exposures.
Market Risks
Foreign Currency Risk
The Company is exposed to currency risk on its sales and purchases denominated in Canadian Dollars. The Company actively manages these risks by adjusting its pricing to reflect currency fluctuations and purchasing foreign currency at advantageous rates.
Interest Rate Risk
The borrowing under the Company’s Line of Credit Facility and Equipment Financing is at variable interest rates and exposes the Company to interest rate risk. If interest rates increase, debt service obligations on variable rate indebtedness will increase even though the amount borrowed may not change.
9. Financial Instruments and Fair Value(continued)
Concentration of Risk
Concentration of Supplier Risk
The Company has historically purchased all of its soft tonneau cover finished goods from Meizhou, China, and it began purchasing soft tonneau cover finished goods from a second supplier in Foshan, China in late 2023. The Company carries significant strategic inventories of these materials and is increasing its purchasing from the supplier in Foshan to lower supplier concentration risk. Further, the Company has established domestic assembly of its hard tonneau cover product line to further reduce the risk associated with this concentration of finished good suppliers. The Company primarily sources raw materials for domestic production and assembly from vendors in Europe, Southeast Asia, and North America. Strategic inventories are managed based on demand. To date, the Company has been able to obtain adequate supplies of the materials used in the production of its products in a timely manner from existing sources. The loss of these key suppliers or a delay in shipments could have an adverse effect on fulfillment of soft tonneau cover orders.
Concentration of Customer Risk
A customer is considered to be significant if they account for greater than 10% of the Company’s annual net sales. The loss of any key customer could have an adverse effect on the Company’s business.
For the year ended December 31, 2025, there are no customers with net sales greater than 10%. For the year ended December 31, 2024,37% of the Company’s net sales was comprised of one customer.
10. Changes in Cash Flows from Operating Assets and Liabilities
The changes to the Company’s operating assets and liabilities for the years ended December 31, 2025 and 2024 are as follows:
| 2025 | 2024 | |
|---|---|---|
| Decrease (increase) in accounts receivable | $(461,382) | $387,561 |
| Decrease (increase) in other receivable | (108,299) | (3,863) |
| Decrease (increase) in inventories | (4,340,617) | (1,558,562) |
| Decrease (increase) in prepaid expenses and deposits | (338,669) | 1,305,057 |
| Increase (decrease) in accounts payable and accrued liabilities | 2,179,473 | 1,167,834 |
| Changes in operating assets and liabilities | $(3,069,494) | $1,298,027 |
11. Leases
The Company accounts for leases under ASC 842, whereby it recognizes a lease liability and a right-of-use asset. The lease liability is measured at the present value of the remaining lease payments, discounted by the Company’s incremental borrowing rate. The Company measured the right of use asset at an initial amount equal to the lease liability.
During the year ended December 31, 2023, the Company signed a lease agreement for office space to be used as an R&D facility pursuant to aone-year lease with an option to extend the lease for an additional year, dated June 1, 2023, for a monthly rent of $3,350. The lease was renewed effective June 1, 2024 at a rate of $3,600 per month with atermination date of May 31, 2025. The lease was not renewed after the initial extension period ended May 31, 2025. The Company’s incremental borrowing rate used to initially measure the present value of the remaining lease payments was 10%.
On April 1, 2025, the Company signed a lease agreement for 12,500 square feet of office space to be used as a R&D facility pursuant to athree-year lease with an option to extend the lease for an additional two years. The lease was effective on May 1, 2025 at a rate of $9,659 per month with a termination date of April 30, 2028. The Company’s incremental borrowing rate used to initially measure the present value of the remaining lease payments was 15%.
On July 14, 2025, the Company signed a lease agreement for 1,992 square feet of office space to be used as an R&D facility for its Terravis Energy subsidiary pursuant to atwo-year lease effective July 18, 2025 for an average monthly rent of $3,154. The Company’s incremental borrowing rate used to initially measure the present value of the remaining lease payments was 15%.
The Company’s right-of-use asset and lease liability as of December 31, 2025 and 2024 is as follows:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Right-of-use asset | $272,598 | $595,415 |
| Current lease liability | $113,012 | $246,535 |
| Long-term lease liability | $159,526 | $368,472 |
The following is a summary of the Company’s total lease costs:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Operating lease cost | $267,608 | $409,464 |
The following is a summary of cash paid in 2025 and 2024 for amounts included in the measurement of lease liabilities:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Operating cashflow | $266,420 | $412,933 |
Maturities of lease liability are as follows:
Future minimum lease payments as of December 31, 2025:
| 2026 | $144,453 |
| 2027 | 134,284 |
| 2028 | 39,783 |
| Total future minimum lease payments | 318,520 |
| Less: amount representing interest | (45,982) |
| Present value of future payments | 272,538 |
| Current portion | 113,012 |
| Long term portion | $159,526 |
12. Indebtedness
Long-term debt consists of:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Revolving Credit Facility (a) | $1,441,665 | $3,808,025 |
| Other (b) | 1,233,493 | 1,456,485 |
| Long-term debt | 2,675,158 | 5,264,510 |
| Less deferred debt issuance cost | (37,868) | (260,513) |
| Less current installments | (1,686,809) | (222,992) |
| Long-term debt | $950,481 | $4,781,005 |
| a) | On July 19, 2024, the Company, as the guarantor, and Worksport New York Operations Corporation as well as Worksport USA Operations Corporation, entered into a $6,000,000 Revolving Financing and Assignment Agreement with an external lending entity with a maturity date of July 18, 2026, or 24 months. Upon transaction close, the Company drew down approximately $5.06 million of the Revolving Credit Facility, net of $790,000 of interest reserve required to be withheld to ensure interest payments by the Company. The Company used $4.73 million of the drawn down amount to refinance the Company’s mortgage on the Company’s real property located at 2500 North America Dr. in West Seneca, New York, and additionally drew approximately $330,000 to fund operations. At December 31, 2025, the outstanding balance of this loan was $1,431,131 (net of issuance costs of $10,534). For collateral, the lender holds a first position on the Company’s major asset classes (accounts receivable, the factory in New York, and inventory) other than the Company’s equipment. A non-usage fee of 0.25% is assessed quarterly and applied to the difference between the quarter’s average daily outstanding loan balance and the total credit facility amount. As of December 31, 2025, the Company had an available balance of $3,448,016 to borrow on the Revolving Credit Facility. |
| b) | On September 4, 2024, the Company, through its wholly owned subsidiary, Worksport USA Operations Corporation, entered into a $1,487,200 credit and security agreement with an external lending entity with a maturity date of September 1, 2027, which is 36 months from initial funding. Upon transaction close, the Company received net proceeds of $1,412,750 (net of issuance costs of $43,735). The Company and its wholly owned subsidiary, Worksport New York Operations Corporation, serve as guarantors on the loan. For collateral, the lender holds a first position on the Company’s equipment, which is primarily manufacturing and warehousing equipment. Interest on the loan is based on the prime rate plus 700 basis points per annum. At December 31, 2025, the outstanding balance of this loan was $1,206,159 (net of issuance costs of $27,334). The Company is in compliance with all covenants. |
13. Loss per Share
For the year ended December 31, 2025, loss per share is $3.16 (basic and diluted) compared to that of the year ended December 31, 2024 of $5.84 (basic and diluted) using the weighted average number of shares of 6,143,122 (basic and diluted) and 2,768,732 (basic and diluted), respectively.
There are 45,000,000 shares authorized with 9,814,665 and 4,016,205 shares issued and outstanding, at December 31, 2025 and 2024, respectively. The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASC 260. Shares underlying the Company’s outstanding warrants and convertible promissory notes were excluded due to the anti-dilutive effect they would have on the computation. As of December 31, 2025, the Company has 7,335,008 warrants convertible to 7,365,008 common shares,472,812 Series C preferred shares convertible to 472,812 common shares,46,504 shares of restricted stock to be issued, and 298,623 stock options exercisable for 298,623 common shares for a total underlying common shares of 8,137,497. As of December 31, 2024, the Company has 2,291,276 warrants convertible to 2,321,276 common shares,117,018 restricted stock to be issued, and 192,784 stock options exercisable for 192,784 common shares for a total underlying common shares of 2,631,078.
14. Warrants
On December 11, 2025, the Company entered into a warrant inducement agreement with the holder of existing warrants to purchase an aggregate 2,194,526 shares at a reduced exercise price of $2.90. Pursuant to the inducement, the existing holder of the existing warrants received 3,840,421 inducement warrants and the Company received $6,364,000 from the exercise of the existing warrants. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental value of $4,485,000 is recorded as a non-cash deemed dividend as a reduction of additional paid in capital based on the Company’s history of net operating losses. The proceeds of the warrant inducement and issuance of 916,000 shares of common stock are recorded as additional paid in capital. The obligation to issue the remaining 1,278,526 shares is recorded as a component of equity.
On September 2, 2025, the Company entered into a consulting agreement with a third party to perform certain services for a six month period in exchange for both cash consideration and the issuance of warrants. The warrant agreement was issued on March 2, 2026 and gives the holder the right to purchase 100,000 shares at $4.00 and 100,000 common shares at $5.00. The warrants expire two years from the date of issuance. The Company determined the fair value provided to the holder at the date of the consulting agreement using the Black Scholes model, as the warrants were earned by the holder over the term of the consulting agreement. For the fiscal year ended December 31, 2025, the Company recognized $216,000 as a component of general and administrative expense.
On June 13, 2025, the Company completed the initial closing of its Regulation A offering whereby up to 3,100,000 units may be sold at an offering price of $3.25 per unit. Each unit consists of one share of 8% Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”) and one warrant for the right to purchase one (1) share of common stock, $0.001 par value, with an exercise price of $4.50 per share. The qualified Regulation A offering is expected to generate gross proceeds of $10,000,000. The proceeds from the Regulation A offering and issuance of units are recorded as additional paid-in capital. On October 15, 2025, the Company completed the Regulation A offering. Through December 31, 2025, the Company issued 3,074,586 warrants to investors.
On February 27, 2025, the Company entered into a warrant inducement agreement with the holder of existing warrants to purchase an aggregate 1,295,000 shares. Pursuant to the inducement, the exercising holder of the existing warrants received 1,425,000 inducement warrants and the Company received $6,731,000 from the exercise of the existing warrants. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from the inducement warrants issued using the Black Scholes model. The total incremental fair value of $7,602,000, is recorded as a non-cash deemed dividend as a reduction of additional paid in capital based on the Company’s history of net operating losses. The proceeds of the warrant inducement and issuance of 1,295,000 shares of common stock are recorded as additional paid-in capital.
During the year ended December 31, 2024, in connection with the sale of 237,224 shares of common stock, the Company also sold 147,789 pre-funded warrants and issued 770,026 warrants exercisable for a total of 770,026 shares of common stock for $0.001 and $7.40, respectively, per share. The Company received net proceeds of $1,093,492 associated with the sale of the pre-funded warrants. The pre-funded warrants are immediately exercisable until all of the pre-funded warrants are exercised. During the same period,147,789 pre-funded warrants were exercised for 147,789 shares of common stock for $150.
During the year ended December 31, 2024, the Company closed a sale of 95,000 shares of common stock. In connection with the sale of common stock the Company issued 190,000 warrants. The warrants have an exercise price of $4.00 and an expiration date of September 21, 2029.
During the year ended December 31, 2024,13,091 warrants issued on August 3, 2021, and 344,652 warrants issued on August 6, 2021, all of which having an exercise price of $60.50, expired.
On May 9, 2024, the Company entered into a warrant inducement agreement with the holder of existing warrants to purchase an aggregate 700,000 shares at a reduced exercise price of $5.198 in consideration for the Company to issue new warrants to purchase up to 1,295,000 additional shares of common stock with an exercise price of $5.198 – resulting in gross proceeds of approximately $3,638,000 received by the Company. As a result of the inducement and subsequent exercise, the Company determined the incremental fair value provided to the holder from both the adjustment in exercise price of the existing warrants and the fair value of the inducement warrants issued using the Black Scholes model. The total incremental fair value of $4,996,000 is recorded as a non-cash deemed dividend as a reduction of additional paid in capital based on the Company’s history of net operating losses. The proceeds of the warrant inducement and issuance of 284,000 shares of common stock are recorded as capital in excess of par. The obligation to issue the remaining 416,000 shares was originally recorded as a share subscription payable. During the twelve months ended December 31, 2024, the Company issued 416,000 out of the 416,000 shares to be issued.
During the year ended December 31, 2023, in connection with the sale of 192,500 shares of common stock the Company also sold 157,500 pre-funded warrants and 700,000 warrants convertible for 857,500 shares of common stock at an exercise price of $0.001 and $13.40, respectively. The Company received net proceeds of $2,110,342 associated with the sale of the pre-funded warrants. During the same period,88,700 pre-funded warrants were exercised for 88,700 shares of common stock for $89. During the year ended December 31, 2024, the remaining 68,800 pre-funded warrants were exercised for 68,800 shares of common stock for $69.
During the year ended December 31, 2023, the Company and a stock options holder agreed to cancel all 40,000 stock options in exchange for extending the exercisable period of 30,000 warrants to December 31, 2024. Later in the year ended December 31, 2023, the expiration date for these warrants was extended to December 31, 2026, and the stock option holder was issued an additional 40,000 restricted stock units.
14. Warrants(continued)
During the year ended December 31, 2022, the Company and a warrant holder reached an agreement to extend the exercisable period of 30,000 warrants, convertible to 2 shares of common stock each, for an additional 12 months.
During the year ended December 31, 2021, the Company issued 13,091 representative warrants to the Company’s underwriters. The representative warrants were not exercisable until January 30, 2022. The representative warrants were exercisable for 13,091 shares of common stock at $60.50 per share until August 3, 2024. As of December 31, 2022, the Company recognized a value of $273,993 for the representative warrants to share issuance cost. During the year ended December 31, 2024, these representative warrants expired.
As of December 31, 2025, the Company has the following warrants outstanding:
| Exercise price | Number outstanding | Remaining Contractual Life (Years) | Expiry date |
|---|---|---|---|
| $40.00 | 30,000 | 1.00 | December 31, 2026 |
| $4.00 | 190,000 | 3.73 | September 21, 2029 |
| $3.00 | 3,840,421 | 5.45 | June 30, 2031 |
| $4.00 – 5.00 | 200,000 | 2.17 | March 2, 2028 |
| $4.50 | 3,074,587 | 2.45 – 2.82 | June 13, 2028 – October 24, 2028 |
| 7,335,008 | 4.12 |
The average remaining contractual life of outstanding warrants that expire is 4.39 years.
| December 31, 2025 | December 31, 2024 | |||
|---|---|---|---|---|
| Number of warrants | Weighted average price | Number of warrants | Weighted average price | |
| Balance, beginning of fiscal year | 2,291,276 | $6.35 | 1,162,792 | $24.20 |
| Issuance | 8,539,508 | $4.16 | 2,402,815 | $5.49 |
| Expired | (6,250) | $24.00 | (357,742) | $60.50 |
| Exercise | (3,489,526) | $6.22 | (916,589) | $(3.97) |
| Balance, end of fiscal year | 7,335,008 | $3.85 | 2,291,276 | $6.35 |
15. Equity Compensation
Under the Company’s 2015, 2021 and 2022 Equity Incentive Plans, the number of shares of common stock reserved for issuance under the option plan shall not exceed 18% of the issued and outstanding shares of common stock of the Company, have a maximum term of 10 years, and vest at the discretion of the Board of Directors.
15. Equity Compensation(continued)
All equity-settled, share-based payments are ultimately recognized as an expense in the statement of operations with a corresponding credit to additional paid in capital. If vesting periods or other non-market vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options expected to vest. Estimates are subsequently revised if there is any indication that the number of share options expected to vest differs from previous estimates. Any cumulative adjustment prior to vesting is recognized in the current period. No adjustment is made to any expense recognized in prior periods if share options ultimately exercised are different than that estimated on vesting.
Performance Share Units
On May 1, 2023, the Company and Steven Rossi reached an agreement to modify 160,000 restricted stock units and 40,000 performance stock units (“PSUs”) issued on November 11, 2022, and December 29, 2021, respectively, and replace them with 200,000 stock options, as described below.
On November 11, 2022,40,000 and 30,000 PSUs granted on December 29, 2021, as described below, were modified to include new terms pertaining to the PSU vesting schedule. The PSUs vest in 5% increments according to the modified schedule that correlates with the Company’s stock price. The first 5% of the PSUs vest upon the Company’s stock price closing at $22.50, 50% will have vested at a closing price of $53.10, and 100% will have vested at a closing price of $137.60 as measured using the volume weighted average of the Company’s common stock for ten (10) consecutive trading days, with over $100,000 of trading volume on each of those days. The fair value of the PSUs was estimated to be $1,254,460. As of December 31, 2025,7,500 PSUs of the remaining 30,000 PSUs had vested, and the Company recognized $107,525 (2024 - $107,525) in consulting expenses.
On December 29, 2021, the Company granted 40,000 and 30,000 PSUs to the Company’s Chief Executive Officer and a director, respectively. The PSUs were to vest in 5% increments according to a schedule that correlates with the Company’s stock price. The first 5% of the PSUs was to have vested upon the Company’s stock price closing at $30.00, 50% was to have vested at a closing price of $165.00, and 100% was to have vested at a closing price of $315.00. The fair value of the PSUs was estimated to be $1,344,570.
Stock Options
The Company uses the Black-Scholes option pricing model to determine fair value of stock options on the grant date.
During the year ended December 31, 2025, the Company issued the following stock options to various directors:
| - | 10,000 stock options vesting ratably over two years, with an exercise price of $5.95 and an expiration date of March 7, 2035 |
| - | 14,000 stock options vesting ratably over two years, with an exercise price of $3.09 and an expiration date of April 4, 2035 |
| - | 30,000 stock options vesting ratably over two years, with an exercise price of $3.80 and an expiration date of July 12, 2035 |
| - | 50,000 stock options vesting pursuant to a performance milestone and an expiration date of July 12, 2035 |
During the year ended December 31, 2025, the Company issued the following stock options to various employees and consultants:
| - | 88,600 stock options vesting based on various service periods, with an exercise price of $3.09 and an expiration date of April 4, 2035 |
| - | 81,940 stock options vesting based on various service periods, with an exercise price of $3.80 and an expiration date of July 12, 2035 |
| - | 76,500 stock options vesting pursuant to performance milestones and an expiration date of July 12, 2035 |
During the year ended December 31, 2025, the Company issued the following stock options to Steven Rossi:
| - | 30,000 stock options vesting 50% at the end of the first two anniversaries of the grant date, with an exercise price of $3.09 and an expiration date of April 4, 2035 |
| - | 215,000 stock options vesting 50% at the end of the first two anniversaries of the grant date, with an exercise price of $3.80, and an expiration date of July 12, 2035. |
On July 23, 2024, the Company engaged in stock option repricing for certain employees, executive officers, and members of the Board of Directors of the Company.538,896 stock options’ exercise prices were repriced to $7.042, and all other criteria were unchanged. As a result of the modification in exercise prices, the Company recognized additional expense of $93,140 on the date of modification.
During the year ended December 31, 2024, the Company issued 84,860 stock options to employees and directors with exercise prices ranging from $5.20 to $14.10 and expiration dates ranging from February 1, 2029 to November 19, 2034. Of these stock options,2,040 were subsequently cancelled.
15. Equity Compensation(continued)
| December 31, 2025 | December 31, 2024 | |||
|---|---|---|---|---|
| Number of stock options | Weighted average price | Number of stock options | Weighted average price | |
| Balance, beginning of fiscal year | 579,936 | $7.14 | 506,386 | $19.62 |
| Granted | 596,040 | $3.68 | 84,860 | $7.70 |
| Forfeited | (4,270) | $9.52 | (11,310) | $(29.30) |
| Balance, end of fiscal year | 1,171,706 | $5.37 | 579,936 | $7.14 |
| Range of Exercise prices | Outstanding | Weighted average life (years) | Weighted average exercise price | Exercisable on December 31, 2025 | |
|---|---|---|---|---|---|
| Stock options | $3.09 – 7.042 | 1,171,706 | 8.22 | $5.37 | 298,609 |
As of December 31, 2025 and December 31, 2024, Terravis Energy Inc., a subsidiary of the Company, has the following options outstanding:
| December 31, 2025 · December 31, 2024 | ||||||
|---|---|---|---|---|---|---|
| Number of stock options · Weighted average price · Number of stock options · Weighted average price | ||||||
| Balance, beginning of fiscal year | 1,350,000 | $0.01 | 1,350,000 | $0.01 | ||
| Granted | - | $ | - | - | $ | - |
| Balance, end of fiscal year | 1,350,000 | $0.01 | 1,350,000 | $0.01 | ||
| Range of Exercise prices | Outstanding | Weighted average life (years) | Weighted average exercise price | Exercisable on December 31, 2025 | |
|---|---|---|---|---|---|
| Stock options | $0.01 | 1,350,000 | 6.28 | $0.01 | 1,350,000 |
16. Segment Reporting
The Company manages its business on a product basis and operates in the followingtwo reporting segments for financial reporting purposes: (1) Hard Tonneau Covers and (2) Soft Tonneau Covers. The accounting policies of both reporting segments are the same as those described in Note 1, Description of Business and Summary of Significant Accounting Policies.
The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer, who regularly reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance of the Company’s reporting segments. The CODM primarily focuses on net income to evaluate its reporting segments. The CODM also uses net income for evaluating pricing strategy and to assess performance for determining the compensation of certain employees. Significant segment expenses reviewed, which represent the differences between segment revenue and segment net loss, consist of the following:
| For the year ended December 31, 2025 · For the year ended December 31, 2024 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hard Tonneau Covers · Soft Tonneau Covers · Corporate / Eliminations · Consolidated · Hard Tonneau Covers · Soft Tonneau Covers · Corporate / Eliminations · Consolidated | ||||||||||
| Net sales | $15,647,276 | $454,462 | $ | - | $16,101,738 | $5,171,201 | $3,313,178 | $ | - | $8,484,379 |
| Less: | ||||||||||
| Cost of sales | (11,272,138) | (350,466) | (4,227) | (11,626,831) | (4,663,491) | (2,915,238) | - | (7,578,729) | ||
| Selling, general and administrative | (10,140,759) | (175,048) | (11,138,218) | (21,454,025) | (5,918,555) | (4,762,105) | (3,937,539) | (14,618,199) | ||
| Depreciation and amortization | (1,676,800) | (37,451) | (120,057) | (1,834,308) | (1,206,499) | (440,916) | (105,870) | (1,753,285) | ||
| Net loss from operations | (7,442,421) | (108,503) | (11,262,502) | (18,813,426) | (6,617,344) | (4,805,081) | (4,043,409) | (15,465,834) | ||
The following table presents the Company’s net sales disaggregated by geographic area:
| 2025 | 2024 | |||||
|---|---|---|---|---|---|---|
| Hard Tonneau Covers | Soft Tonneau Covers | Consolidated | Hard Tonneau Covers | Soft Tonneau Covers | Consolidated | |
| United States | $15,558,123 | $451,960 | $16,010,083 | $5,111,377 | $3,286,193 | $8,397,570 |
| Other | 89,153 | 2,502 | 91,655 | 59,824 | 26,985 | 86,809 |
| Total | 15,647,276 | 454,462 | 16,101,738 | 5,171,201 | 3,313,178 | 8,484,379 |
No asset information has been provided for the reported segments as the CODM does not regularly review asset information by reportable segment. As of December 31, 2025 and 2024, assets held in the U.S. accounted for 93% and 88% of total assets, respectively.
17. Legal Proceedings
There are no legal proceedings except for routine litigation incidental to the business.
18. Subsequent Events
The Company has evaluated subsequent events through March 26, 2026, which is the date the financial statements were available to be issued. The following events occurred after year-end:
| ● | Through March 26, 2026, the Company has sold and issued 2,070,654 shares of common stock in consideration for net proceeds of $2,113,000 under the ATM Agreement. |
| ● | Through March 26, 2026, 200 shares of Series C Preferred stock were converted to 200 shares of common stock at the request of the investor. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.